Cloning of CTB-PROIN fusion gene and its expression in Escherichia coli.
- Author:
Li CHEN
1
;
Feng-Xiu OUYANG
;
Bing-Jun QIAN
;
Hong REN
;
Qiang WANG
;
Qing-Wu JIANG
;
Yu-Jiong WANG
;
Jing-Bo LIU
;
Wan-Qi LIANG
;
Da-Bing ZHANG
Author Information
1. Life Science School of Ningxia University, Yinchuan 750021, China.
- Publication Type:Journal Article
- MeSH:
Artificial Gene Fusion;
Cholera Toxin;
genetics;
Cloning, Molecular;
Escherichia coli;
genetics;
metabolism;
G(M1) Ganglioside;
metabolism;
Proinsulin;
genetics;
Recombinant Proteins;
biosynthesis;
genetics
- From:
Chinese Journal of Biotechnology
2005;21(2):204-210
- CountryChina
- Language:Chinese
-
Abstract:
A fusion gene CTB-PROIN, in which Proinsulin gene was fused to the 3' end of CTB gene by a hinge peptide 'GPGP', was constructed and cloned into pET-30a(+) to obtain a prokaryotic expression vector pETCPI. Subsequently the recombinant plasmid pETCPI was transformed into E. coli stain BL21 (DE3). After induced by IPTG, the expression product was analyzed by sodium dodecyl sulphate-polyacrylamide gel (15%) electrophoresis (SDS-PAGE), and its result indicated that the recombinant protein CTB-PROIN was expressed and accumulated as inclusion bodies. The recombinant CTB-PROIN protein accumulated to the level of 25% of total bacterial proteins. After inclusion bodies was denaturalized and refolded in vitro, significant assembly of monomers had occurred, and the recombinant protein represented assembled pentamers. The results of western blotting analysis also demonstrated that the fusion protein could be recognized by the anti-CT and anti-insulin antibody, respectively. In addition, the result of the CTB-PROIN-GM1 binding assay, that the protein could bind to monosialoganglioside specifically, showed it possesed biological activity in vitro. These results provided the possibility of developing a cheaper and more efficient oral vaccine for type I diabetes using such constructs.
